Who is sponsoring NCT03130868?

NCT03130868 is sponsored by HealthPartners Institute.

What drugs are being tested in NCT03130868?

Interventions in NCT03130868: Characterizing changes in the microbiome.

What condition does NCT03130868 study?

NCT03130868 studies Burns Greater Than 20% BSAB, Burns.

Is NCT03130868 still recruiting?

NCT03130868 is currently completed. Last updated 1 August 2018.

Last reviewed 2018-08-01 · How we verify

NCT03130868: Microbiome

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microbiome Changes in Severe Burns

Completed Last updated 1 August 2018

What this trial tests

trial testing Characterizing changes in the microbiome in Burns Greater Than 20% BSAB in 2 participants. Completed in 2 July 2018.

Timeline

15 May 2017

Primary endpoint
2 July 2018

2 July 2018

Quick facts

Lead sponsor	HealthPartners Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2
Start date	15 May 2017
Primary completion	2 July 2018
Estimated completion	2 July 2018
Sites	1 location across United States

Drugs / interventions tested

Characterizing changes in the microbiome

Conditions studied

Burns Greater Than 20% BSAB — all drugs for Burns Greater Than 20% BSAB →
Burns — all drugs for Burns →

Sponsor

HealthPartners Institute

Who can join

Adults 17 to 120, any sex, with Burns Greater Than 20% BSAB or Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is characterizing changes in the microbiome of severely-injured adult patients as they progress through stages of injury, reconstruction, and recovery from burns.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other HealthPartners Institute trials

Trials by the same sponsor.

NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei · NA · not yet recruiting
NCT07354919 — Axelopran in Advanced Cancers · Phase 2 · not yet recruiting
NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age · Phase 1 · withdrawn
NCT06914726 — Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes · NA · enrolling by invitation
NCT06999330 — TMS in Anxiety-Parkinson's Disease · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03130868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
Last refreshed: 1 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03130868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing